Disclaimer:
This blog is for informational purposes only and should not be taken as medical advice. Content is sourced from third parties, and we do not guarantee accuracy or accept any liability for its use. Always consult a qualified healthcare professional for medical guidance.
Thymus cancer arises in the thymus, a small organ in the chest behind the sternum, crucial for T-cell maturation in the immune system. It includes thymomas (slow-growing, 90%) and thymic carcinomas (aggressive, 10%), with subtypes based on WHO classification (A, AB, B1-B3 for thymomas; squamous for carcinomas). Extremely rare, it accounts for <1% of cancers, with ~500 US cases annually in 2025, affecting adults aged 40-60 equally across genders. Often associated with autoimmune disorders like myasthenia gravis (30-50% of thymoma cases), it ranges from encapsulated to metastatic.
Many cases are asymptomatic, found incidentally on imaging. Symptoms include chest pain, persistent cough, shortness of breath (from mediastinal compression), superior vena cava syndrome (facial/arm swelling, cyanosis), fatigue, weight loss, and night sweats. Paraneoplastic syndromes like myasthenia gravis (muscle weakness, drooping eyelids), pure red cell aplasia, or hypogammaglobulinemia occur in 40% of thymomas. Advanced cases cause pleural effusion or symptoms from metastases (lungs, liver). Symptoms may mimic pneumonia or heart disease, delaying diagnosis.
Causes are unknown, but risk factors include autoimmune diseases (myasthenia gravis, lupus), radiation exposure, and genetic alterations (GTF2I mutations in thymomas, KIT/EGFR in carcinomas). No strong lifestyle links exist, but thymic epithelial cell dysregulation is key. In 2025, research highlights immune microenvironment and PD-L1 expression as drivers, with no clear environmental triggers.
Diagnosis uses chest CT/MRI to detect mediastinal masses, PET for metabolic activity, and biopsy (core/needle) for histology. Blood tests assess paraneoplastic markers (anti-acetylcholine receptor antibodies). Staging uses Masaoka-Koga (I-IV). In 2025, AI imaging differentiates thymomas from lymphomas, and molecular profiling (NGS) identifies actionable mutations.
Stage I-II thymomas use surgical resection (thymectomy via sternotomy or VATS), achieving 90-95% cure. Stage III-IV or thymic carcinomas combine surgery, radiation (IMRT), and chemotherapy (cisplatin, doxorubicin). Targeted therapies (sunitinib for KIT mutations) and immunotherapy (pembrolizumab for PD-L1+) show 20-30% response in advanced cases. In 2025, minimally invasive surgery and proton therapy reduce complications, with autoimmune management critical.
In 2025, 5-year survival is 90% for stage I thymomas, 70% for stage III, and 30-50% for thymic carcinomas. Advances in targeted therapies extend survival by 12-18 months in metastatic cases. Research on immune modulators and CAR-T could raise survival to 80% for advanced by 2030, with focus on managing paraneoplastic syndromes.
Cleveland Clinic’s “Thymus Cancer: Symptoms, Causes & Treatment”; Mayo Clinic’s “Thymoma and Thymic Carcinoma – Symptoms and causes”; NCI’s “Thymoma and Thymic Carcinoma Treatment (PDQ®)”; American Cancer Society’s “Thymus Cancer”; PMC’s “Thymus Cancer: Advances in 2025”.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
1. Scan at your preferred center.
2. Written report from a specialist radiologist sent via email.
3. Access and download your scan images digitally.
4. Upon request, we can send the report and images to your doctor or hospital.
5. For self-referred patients, there is an additional charge of £30, which includes scan referral and a discussion with a private GP before and after the scan